抗菌薬感受性試験市場：製品（手動、自動）、タイプ（抗菌、抗真菌）、用途（臨床診断）、方法（ETEST、ディスク拡散、寒天拡散、ジェノタイピング）、エンドユーザー＆地域別 - 2027年までの世界予測

Antimicrobial Susceptibility Testing Market by Product (Manual, Automated), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion, Agar Diffusion, Genotyping), End User & Region - Global Forecasts to 2027

抗菌薬感受性検査市場は、予測期間中に5.5%のCAGRで、2022年の36億米ドルから2027年には47億米ドルに達すると予測されます。抗菌薬感受性検査市場の著しい成長は、耐性微生物（AMR）を復活させる抗生物質の過剰使... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年3月1日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	237	201	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

抗菌薬感受性検査市場は、予測期間中に5.5%のCAGRで、2022年の36億米ドルから2027年には47億米ドルに達すると予測されます。抗菌薬感受性検査市場の著しい成長は、耐性微生物（AMR）を復活させる抗生物質の過剰使用や誤用、バイオ医薬品、バイオテクノロジー、製薬会社による抗菌薬感受性検査の利用拡大が大きな要因です。

"2022年、自動化されたラボラトリー機器が最大のシェアを占める"
2022年には、自動化された検査機器が最大の市場シェアを占める。自動化された同定および感受性システムは、従来の手動式のものよりも高価ですが、より迅速な発見ができるという利点があります。自動化された方法はより効率的で高品質ですが、一部の細菌や抗菌剤には特有の技術的な制約があります。

"2022年、抗菌性感染症が最大シェアを占める"
抗菌薬感受性試験市場は、タイプ別に、抗菌薬感受性試験、抗真菌薬感受性試験、抗寄生虫薬感受性試験、その他の感受性試験に分類されます。この分野で大きなシェアを占めているのは、抗菌薬感受性試験のプロセスを合理化するための規制ガイドラインの存在、この分野における技術的進歩、発展途上国および先進国における抗菌薬耐性の負担増などに起因しているものと思われる。

"予測期間中、北米地域の市場が最も高い成長を遂げると予想される"
2022年の市場シェアは、北米が35.4%で最大となった。新規の自動ASTシステムを開発するための研究開発の増加、感染症の流行、安全性への懸念の高まり、抗菌薬感受性試験製品の技術的進歩が、北米の市場成長を支える主な要因となっている
一方、APACは今後数年間で大きな成長を遂げると予想されています。APAC地域の抗菌薬感受性試験市場は、主にアジア諸国の病院数の増加や政府の有利な取り組みにより、予測期間中に6.7%のCAGRを記録すると予想されます。

本レポートで参照した主な参加者の内訳は以下のとおりです：
- 企業タイプ別ティア1-40％、ティア2-30％、ティア3-30％：ティア1-40％、ティア2-30％、ティア3-30％。
- 役職別Cレベル-27％、ディレクターレベル-18％、その他-55
- 地域別北米35.3％、欧州20％、アジア太平洋15％、中南米10％、中近東・アフリカ5

抗菌薬感受性試験の主要プレーヤーは、bioMérieux SA（フランス）、Becton, Dickinson and Company（米国）、Thermo Fisher Scientific（米国）、Danaher Corporation（米国）、Bio-Rad Laboratories, Inc（米国）となっています。

調査対象

本レポートでは、製品、デザイン、エンドユーザー、地域に基づき、抗菌剤感受性試験市場を調査します。また、市場成長に影響を与える要因を網羅し、市場における様々な機会や課題を分析し、市場リーダーのための競争環境の詳細を提供します。さらに、ミクロ市場を個々の成長動向に関して分析し、主要5地域（およびこれらの地域のそれぞれの国）に関して、市場セグメントの収益を予測しています。

レポート購入の理由
本レポートは、既存企業や新規参入企業・中小企業が市場の動向を把握し、より大きな市場シェアを獲得するための一助となるものです。本レポートを購入された企業は、以下の戦略の1つまたは複数を組み合わせて、市場でのプレゼンスを強化することができます。

本レポートでは、以下のポイントについて考察しています：
- 市場の浸透度：マイクロカテーテル市場のトッププレイヤーが提供する製品ポートフォリオに関する包括的な情報。
- 製品開発/イノベーション：マイクロカテーテル市場における今後の動向、研究開発活動、製品発売に関する詳細なインサイトを提供します。
- 市場開発：有利な新興地域に関する包括的な情報
- 市場の多様化：マイクロカテーテル市場の新製品、成長地域、最新動向に関する情報を網羅。
- 競争力のある評価：市場セグメント、成長戦略、収益分析、主要市場プレイヤーの製品に関する詳細な評価。

ページTOPに戻る

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS AND EXCLUSIONS 30
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
1.3.2 REGIONS COVERED 31
1.3.3 YEARS CONSIDERED 31
1.4 CURRENCY CONSIDERED 31
1.5 STAKEHOLDERS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 1 RESEARCH DESIGN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 34
2.1.1 SECONDARY DATA 35
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
FIGURE 2 PRIMARY SOURCES 37
2.1.2.1 Key data from primary sources 38
2.1.2.2 Insights from primary experts 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 41
FIGURE 5 TOP-DOWN APPROACH 42
FIGURE 6 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 42
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ESTIMATION 45
2.5 RESEARCH ASSUMPTIONS 45
2.6 LIMITATIONS 45
2.6.1 METHODOLOGY-RELATED LIMITATIONS 45
2.7 RISK ASSESSMENT 46
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS 46
2.8 IMPACT OF RECESSION ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 46

3 EXECUTIVE SUMMARY 47
FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 47
FIGURE 9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY TYPE, 2022 VS. 2027 48
FIGURE 10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 49
FIGURE 11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022 VS. 2027 (USD MILLION) 50
FIGURE 12 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY END USER, 2022 VS. 2027 50
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 51
4 PREMIUM INSIGHTS 52
4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW 52
FIGURE 14 TECHNOLOGICAL ADVANCEMENTS AND RISING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 52
4.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 53
FIGURE 15 SUSCEPTIBILITY TESTING DISKS SEGMENT TO DOMINATE MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET 53
4.3 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY AND TYPE 54
FIGURE 16 ANTIBACTERIAL SUSCEPTIBILITY TESTING SEGMENT TO DOMINATE NORTH AMERICAN MARKET 54
4.4 GEOGRAPHIC SNAPSHOT: KEY GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 55
FIGURE 17 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 18 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Rising incidence of infectious diseases coupled with epidemic and pandemic events 57
5.2.1.2 Increasing funding, research grants, and public-private investments 58
5.2.1.3 Technological advancements 59
5.2.1.4 Growing government initiatives to detect and control antimicrobial-resistant species 61
5.2.1.5 Emergence of multidrug resistance due to drug abuse 62
5.2.2 RESTRAINTS 62
5.2.2.1 High cost of automated ID/AST systems 62

5.2.3 OPPORTUNITIES 63
5.2.3.1 Growth opportunities in emerging markets 63
5.2.4 CHALLENGES 63
5.2.4.1 Complex regulatory frameworks 63
5.3 PORTER’S FIVE FORCES ANALYSIS 64
5.3.1 OVERVIEW 64
TABLE 2 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 64
5.3.2 THREAT OF NEW ENTRANTS 64
5.3.3 THREAT OF SUBSTITUTES 64
5.3.4 BARGAINING POWER OF SUPPLIERS 64
5.3.5 BARGAINING POWER OF BUYERS 65
5.3.6 INTENSITY OF COMPETITIVE RIVALRY 65
5.4 REGULATORY ANALYSIS 65
5.4.1 NORTH AMERICA 65
5.4.1.1 US 65
TABLE 3 US FDA: MEDICAL DEVICE CLASSIFICATION 65
TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 66
5.4.1.2 Canada 66
TABLE 5 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 66
5.4.2 EUROPE 67
5.4.3 ASIA PACIFIC 67
5.4.3.1 Japan 67
TABLE 6 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS AND MEDICAL DEVICES AGENCY 68
5.4.3.2 China 68
TABLE 7 CHINA: CLASSIFICATION OF MEDICAL DEVICES 68
5.4.3.3 India 69
5.5 ECOSYSTEM ANALYSIS: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 70
FIGURE 19 ECOSYSTEM COVERAGE 70
5.6 VALUE CHAIN ANALYSIS 70
5.6.1 RESEARCH & DEVELOPMENT 71
5.6.2 MANUFACTURING AND ASSEMBLY 71
5.6.3 DISTRIBUTION, MARKETING AND SALES, AND POST-SALES SERVICES 71
FIGURE 20 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: VALUE CHAIN ANALYSIS 71
5.7 SUPPLY CHAIN ANALYSIS 72
5.7.1 PROMINENT COMPANIES 72
5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES 72
FIGURE 21 SUPPLY CHAIN ANALYSIS 72
5.8 KEY CONFERENCES AND EVENTS IN 2023–2024 72
TABLE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES AND EVENTS 72

5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 73
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS 73
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS 73
5.9.2 BUYING CRITERIA 74
FIGURE 23 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS 74
TABLE 10 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS 74
5.10 PATENT ANALYSIS 75
FIGURE 24 TOP 10 PATENT APPLICANTS 75
FIGURE 25 TOP 10 PATENT OWNERS 76
6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT 77
6.1 INTRODUCTION 78
TABLE 11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 78
6.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS 78
TABLE 12 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 13 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION) 79
6.2.1 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE 80
TABLE 14 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
6.2.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION 80
TABLE 15 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 80
6.2.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD 81
TABLE 16 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD, 2020–2027 (USD MILLION) 81
6.2.4 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER 81
TABLE 17 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 81
6.2.5 SUSCEPTIBILITY TESTING DISKS 82
6.2.5.1 Significant adoption of disk diffusion tests in emerging countries to support segment growth 82
TABLE 18 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2020–2027 (USD MILLION) 82
6.2.5.2 Susceptibility testing disks market, by type 83
TABLE 19 SUSCEPTIBILITY TESTING DISKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 83
6.2.5.3 Susceptibility testing disks market, by application 83
TABLE 20 SUSCEPTIBILITY TESTING DISKS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 83
6.2.5.4 Susceptibility testing disks market, by method 84
TABLE 21 SUSCEPTIBILITY TESTING DISKS MARKET, BY METHOD, 2020–2027 (USD MILLION) 84
6.2.5.5 Susceptibility testing disks market, by end user 84
TABLE 22 SUSCEPTIBILITY TESTING DISKS MARKET, BY END USER, 2020–2027 (USD MILLION) 84
6.2.6 MIC STRIPS 84
6.2.6.1 Growing adoption of broad-spectrum MIC strips to support market growth 84
TABLE 23 MIC STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION) 85
6.2.6.2 MIC strips market, by type 85
TABLE 24 MIC STRIPS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85
6.2.6.3 MIC strips market, by application 86
TABLE 25 MIC STRIPS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86
6.2.6.4 MIC strips market, by method 86
TABLE 26 MIC STRIPS MARKET, BY METHOD, 2020–2027 (USD MILLION) 86
6.2.6.5 MIC strips market, by end user 87
TABLE 27 MIC STRIPS MARKET, BY END USER, 2020–2027 (USD MILLION) 87
6.2.7 SUSCEPTIBILITY TESTING PLATES 87
6.2.7.1 Increasing adoption of automated/rapid AST systems hampering growth 87
TABLE 28 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION, 2020–2027 (USD MILLION) 88
6.2.7.2 Susceptibility testing plates market, by type 88
TABLE 29 SUSCEPTIBILITY TESTING PLATES MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
6.2.7.3 Susceptibility testing plates market, by application 89
TABLE 30 SUSCEPTIBILITY TESTING PLATES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89
6.2.7.4 Susceptibility testing plates market, by method 89
TABLE 31 SUSCEPTIBILITY TESTING PLATES MARKET, BY METHOD, 2020–2027 (USD MILLION) 89
6.2.7.5 Susceptibility testing plates market, by end user 90
TABLE 32 SUSCEPTIBILITY TESTING PLATES MARKET, BY END USER, 2020–2027 (USD MILLION) 90
6.3 AUTOMATED LABORATORY INSTRUMENTS 90
6.3.1 ONGOING TREND OF LABORATORY AUTOMATION AMONG CLINICAL LABORATORIES TO FUEL GROWTH 90
TABLE 33 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 91
6.3.2 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE 92
TABLE 34 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 92
6.3.3 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION 92
TABLE 35 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 92
6.3.4 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD 93
TABLE 36 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD, 2020–2027 (USD MILLION) 93
6.3.5 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER 93
TABLE 37 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 93
6.4 CULTURE AND GROWTH MEDIA 94
6.4.1 HIGH UTILIZATION OF DISK DIFFUSION AND BROTH DILUTION METHODS TO DRIVE GROWTH 94
TABLE 38 CULTURE AND GROWTH MEDIA MARKET, BY REGION, 2020–2027 (USD MILLION) 94
6.4.2 CULTURE AND GROWTH MEDIA MARKET, BY TYPE 95
TABLE 39 CULTURE AND GROWTH MEDIA MARKET, BY TYPE, 2020–2027 (USD MILLION) 95
6.4.3 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION 95
TABLE 40 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95
6.4.4 CULTURE AND GROWTH MEDIA MARKET, BY METHOD 96
TABLE 41 CULTURE AND GROWTH MEDIA MARKET, BY METHOD, 2020–2027 (USD MILLION) 96
6.4.5 CULTURE AND GROWTH MEDIA MARKET, BY END USER 96
TABLE 42 CULTURE AND GROWTH MEDIA MARKET, BY END USER, 2020–2027 (USD MILLION) 96
6.5 CONSUMABLES 97
6.5.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED AT HOSPITALS TO SUPPORT GROWTH 97
TABLE 43 CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 97
6.5.2 CONSUMABLES MARKET, BY TYPE 98
TABLE 44 CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 98
6.5.3 CONSUMABLES MARKET, BY APPLICATION 98
TABLE 45 CONSUMABLES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
6.5.4 CONSUMABLES MARKET, BY METHOD 99
TABLE 46 CONSUMABLES MARKET, BY METHOD, 2020–2027 (USD MILLION) 99
6.5.5 CONSUMABLES MARKET, BY END USER 99
TABLE 47 CONSUMABLES MARKET, BY END USER, 2020–2027 (USD MILLION) 99
7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 100
7.1 INTRODUCTION 101
TABLE 48 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING 101
7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS 101
TABLE 49 ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 102
7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING 102
7.3.1 INCREASING INFECTIONS OF CANDIDA AND ASPERGILLUS SPECIES TO DRIVE GROWTH 102
TABLE 50 NUMBER OF HOSPITALIZATIONS AND DIRECT MEDICAL COSTS ASSOCIATED WITH FUNGAL DISEASES IN US FOR FY 2019 103
TABLE 51 ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 103
7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING 104
7.4.1 RISING INITIATIVES TO CREATE AWARENESS ABOUT PARASITIC INFECTIONS TO DRIVE GROWTH 104
TABLE 52 ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 104
7.5 OTHER SUSCEPTIBILITY TESTING 105
TABLE 53 OTHER SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 105
8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 106
8.1 INTRODUCTION 107
TABLE 54 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107
8.2 CLINICAL DIAGNOSTICS 107
8.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED TO DRIVE GROWTH 107
TABLE 55 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 108
8.3 DRUG DISCOVERY AND DEVELOPMENT 108
8.3.1 RISING ADOPTION OF RAPID AST SOLUTIONS BY BIOPHARMACEUTICAL COMPANIES TO DRIVE SEGMENT GROWTH 108
TABLE 56 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 109
8.4 EPIDEMIOLOGY 109
8.4.1 OUTBREAK OF PANDEMICS AND EPIDEMICS TO DRIVE DEMAND FOR AST PRODUCTS 109
TABLE 57 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY, BY REGION, 2020–2027 (USD MILLION) 110
8.5 OTHER APPLICATIONS 110
TABLE 58 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 111

9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD 112
9.1 INTRODUCTION 113
TABLE 59 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 113
9.2 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING 113
9.2.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE TO DRIVE GROWTH 113
TABLE 60 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 115
9.3 DISK DIFFUSION 115
9.3.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO DRIVE GROWTH 115
TABLE 61 DISK DIFFUSION-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 116
9.4 AGAR DILUTION 116
9.4.1 AGAR DILUTION HELPS EXPLORE DRUG COMBINATIONS FOR COMBINED ANTIBIOTIC THERAPY 116
TABLE 62 AGAR DILUTION-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 117
9.5 ETEST 117
9.5.1 UNCERTAINTIES IN RESULT INTERPRETATION AFFECTING MARKET GROWTH 117
TABLE 63 ETEST-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 118
9.6 GENOTYPIC METHODS 118
9.6.1 ONGOING CLINICAL TRIALS AND UPCOMING PRODUCT LAUNCHES SUPPORT GROWTH 118
TABLE 64 GENOTYPIC METHODS-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 119
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 120
10.1 INTRODUCTION 121
TABLE 65 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 121
10.2 HOSPITALS AND DIAGNOSTIC CENTERS 121
10.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES AND RISING ADOPTION OF RAPID AST SOLUTIONS TO DRIVE GROWTH 121
TABLE 66 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 122
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 122
10.3.1 INCREASING NUMBER OF BIOPHARMACEUTICAL COMPANIES TO SUPPORT SEGMENT GROWTH 122
TABLE 67 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 123

10.4 RESEARCH AND ACADEMIC INSTITUTES 123
10.4.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH 123
TABLE 68 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020 124
TABLE 69 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 124
10.5 CONTRACT RESEARCH ORGANIZATIONS 125
10.5.1 CLINICAL TRIAL GLOBALIZATION AND GROWING NUMBER OF CROS IN EMERGING ECONOMIES TO DRIVE GROWTH 125
TABLE 70 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 125
11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION 126
11.1 INTRODUCTION 127
TABLE 71 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 127
11.2 NORTH AMERICA 127
FIGURE 26 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT 128
TABLE 72 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 73 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 129
TABLE 74 NORTH AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 75 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 76 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 77 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 131
TABLE 78 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 131
11.2.1 US 131
11.2.1.1 US to dominate North American market during forecast period 131
TABLE 79 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 132
TABLE 80 US: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
11.2.2 CANADA 133
11.2.2.1 Favorable government initiatives to drive growth during forecast period 133
TABLE 81 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133
TABLE 82 CANADA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 134

11.3 EUROPE 134
TABLE 83 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
TABLE 84 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 135
TABLE 85 EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 86 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 87 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136
TABLE 88 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 137
TABLE 89 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 137
11.3.1 GERMANY 137
11.3.1.1 Germany to dominate European market during forecast period 137
TABLE 90 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 138
TABLE 91 GERMANY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
11.3.2 FRANCE 139
11.3.2.1 Supportive government policies and easy access to healthcare services to fuel growth 139
TABLE 92 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 140
TABLE 93 FRANCE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
11.3.3 UK 140
11.3.3.1 Significant prevalence of infectious diseases coupled with increasing awareness of AST products to drive market growth 140
TABLE 94 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 141
TABLE 95 UK: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
11.3.4 ITALY 142
11.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand for AST products 142
TABLE 96 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 142
TABLE 97 ITALY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
11.3.5 SPAIN 143
11.3.5.1 Rising geriatric population to drive market growth 143
TABLE 98 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 144
TABLE 99 SPAIN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
11.3.6 REST OF EUROPE 144
TABLE 100 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 145
TABLE 101 REST OF EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 145
11.4 ASIA PACIFIC 146
FIGURE 27 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT 147
TABLE 102 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 103 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 148
TABLE 104 ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 105 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 106 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 107 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 150
TABLE 108 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 151
11.4.1 JAPAN 151
11.4.1.1 Growing geriatric population to drive market 151
TABLE 109 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 152
TABLE 110 JAPAN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
11.4.2 CHINA 152
11.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth 152
TABLE 111 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020 153
TABLE 112 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 153
TABLE 113 CHINA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
11.4.3 INDIA 154
11.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth 154
TABLE 114 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 155
TABLE 115 INDIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
11.4.4 AUSTRALIA 155
11.4.4.1 Increasing government funding for research activities to drive market growth 155
TABLE 116 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 156
TABLE 117 AUSTRALIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
11.4.5 SOUTH KOREA 157
11.4.5.1 Requirement of rapid AMR detection to drive growth 157
TABLE 118 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 157
TABLE 119 SOUTH KOREA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
11.4.6 REST OF ASIA PACIFIC 158
TABLE 120 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 158
TABLE 121 REST OF ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
11.5 LATIN AMERICA 159
TABLE 122 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
TABLE 123 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 160
TABLE 124 LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 125 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 126 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 127 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 162
TABLE 128 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 163
11.5.1 BRAZIL 163
11.5.1.1 Established presence of major AST product manufacturers to drive growth 163
TABLE 129 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 164
TABLE 130 BRAZIL: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
11.5.2 MEXICO 164
11.5.2.1 Growing economic development to drive market growth 164
TABLE 131 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 165
TABLE 132 MEXICO: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
11.5.3 REST OF LATIN AMERICA 166
TABLE 133 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 166
TABLE 134 REST OF LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 166

11.6 MIDDLE EAST & AFRICA 167
11.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH 167
TABLE 135 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 167
TABLE 136 MIDDLE EAST & AFRICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 137 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 138 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 169
TABLE 139 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 169
TABLE 140 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 170
12 COMPETITIVE LANDSCAPE 171
12.1 INTRODUCTION 171
12.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN 171
TABLE 141 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 171
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 173
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 173
12.4 MARKET SHARE ANALYSIS (2021) 174
FIGURE 29 BIOMÉRIEUX SA HELD LEADING POSITION IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET IN 2021 174
12.5 COMPANY EVALUATION MATRIX FOR 25 MAJOR PLAYERS (2021) 174
12.5.1 STARS 175
12.5.2 EMERGING LEADERS 175
12.5.3 PERVASIVE PLAYERS 175
12.5.4 PARTICIPANTS 175
FIGURE 30 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2021 176
12.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021) 177
12.6.1 PROGRESSIVE COMPANIES 177
12.6.2 RESPONSIVE COMPANIES 177
12.6.3 DYNAMIC COMPANIES 177
12.6.4 STARTING BLOCKS 177
FIGURE 31 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2021 178
12.7 COMPETITIVE BENCHMARKING 179
TABLE 142 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 179
TABLE 143 APPLICATION FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 180
TABLE 144 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 181
12.8 COMPETITIVE SCENARIO 182
12.8.1 PRODUCT LAUNCHES 182
TABLE 145 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2020–JANUARY 2023 182
12.8.2 DEALS 184
TABLE 146 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DEALS, JANUARY 2020–JANUARY 2023 184
13 COMPANY PROFILES 186
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS 186
13.1.1 BIOMÉRIEUX SA 186
TABLE 147 COMPANY OVERVIEW: BIOMÉRIEUX SA 186
FIGURE 32 BIOMÉRIEUX SA: COMPANY SNAPSHOT 187
13.1.2 BECTON, DICKINSON AND COMPANY 191
TABLE 148 COMPANY OVERVIEW: BECTON, DICKINSON AND COMPANY 191
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 192
13.1.3 THERMO FISHER SCIENTIFIC 194
TABLE 149 COMPANY OVERVIEW: THERMO FISHER SCIENTIFIC 194
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 195
13.1.4 DANAHER CORPORATION 198
TABLE 150 COMPANY OVERVIEW: DANAHER CORPORATION 198
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT 199
13.1.5 BIO-RAD LABORATORIES, INC. 202
TABLE 151 COMPANY OVERVIEW: BIO-RAD LABORATORIES, INC. 202
FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 203
13.1.6 BRUKER 205
TABLE 152 COMPANY OVERVIEW: BRUKER 205
FIGURE 37 BRUKER: COMPANY SNAPSHOT 206
13.1.7 ROCHE DIAGNOSTICS 208
TABLE 153 COMPANY OVERVIEW: ROCHE DIAGNOSTICS 208
FIGURE 38 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 209
13.1.8 MERCK KGAA 211
TABLE 154 COMPANY OVERVIEW: MERCK KGAA 211
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT 212
13.1.9 ACCELERATE DIAGNOSTICS, INC. 215
TABLE 155 COMPANY OVERVIEW: ACCELERATE DIAGNOSTICS, INC. 215
FIGURE 40 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT 216
13.1.10 HIMEDIA LABORATORIES 218
TABLE 156 COMPANY OVERVIEW: HIMEDIA LABORATORIES 218

13.1.11 LIOFILCHEM S.R.L. 220
TABLE 157 COMPANY OVERVIEW: LIOFILCHEM S.R.L. 220
13.1.12 ALIFAX S.R.L. 223
TABLE 158 COMPANY OVERVIEW: ALIFAX S.R.L. 223
13.1.13 CREATIVE DIAGNOSTICS 225
TABLE 159 COMPANY OVERVIEW: CREATIVE DIAGNOSTICS 225
13.1.14 SYNBIOSIS 227
TABLE 160 COMPANY OVERVIEW: SYNBIOSIS 227
13.1.15 BIOANALYSE 228
TABLE 161 COMPANY OVERVIEW: BIOANALYSE 228
13.2 OTHER COMPANIES 229
13.2.1 ZHUHAI DL BIOTECH CO., LTD. 229
13.2.2 ELITECH GROUP 230
13.2.3 MAST GROUP LTD. 231
13.2.4 CONDALAB 231
13.2.5 GENEFLUIDICS, INC. 232
13.2.6 BIOTRON LTD. 232
13.2.7 INVIVOGEN 233
13.2.8 MP BIOMEDICALS 233
13.2.9 QUANTAMATRIX INC. 234
13.2.10 PML MICROBIOLOGICALS 234
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 235
14.1 DISCUSSION GUIDE 235
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 240
14.3 CUSTOMIZATION OPTIONS 242
14.4 RELATED REPORTS 242
14.5 AUTHOR DETAILS 243

ページTOPに戻る

Table of Contents

Summary

The Antimicrobial Susceptibility Testing market is projected to reach USD 4.7 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 5.5% during the forecast period. The significant growth of the antimicrobial susceptibility testing market is largely due to the overuse and misuse of antibiotics, which resuresistance microbial resistances (AMR), and the increased use of antimicrobial susceptibility testing by biopharmaceutical, biotechnological, and pharmaceutical companies.

“The automated laboratory instruments to hold the largest share of the market in 2022”
Automated laboratory instruments holds the largest market share in 2022. Automated identification and susceptibility systems are more expensive than manual conventional ones but offer the advantage of quicker findings. Although automated methods are more efficient and of higher quality, some bacteria and antimicrobial agents have specific technological limitations.

“The Antibacterial infections is holding the largest share of the market in 2022”
Based on type, the antimicrobial susceptibility testing market is classified into antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing and other susceptibility testing. The large share of this segment is attributed to the presence of regulatory guidelines to streamline the process of antibacterial susceptibility testing, technological advancements in this segment, and the rising burden of antibacterial resistance in developing and developed countries.

“The market in North America region is expected to witness the highest growth during the forecast period.”
North America accounted for the largest market share—35.4%—in 2022. The increasing R&D to develop novel automated AST systems, rising prevalence of infectious diseases, growing safety concerns, and technological advancements in antimicrobial susceptibility testing products are the key factors supporting market growth in North America
While the APAC is expected to witness significant growth in the coming years. The antimicrobial susceptibility testing market in the APAC region is expected to register a CAGR of 6.7% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18%, and Others–55%
• By Region: North America–35.3%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

The prominent player in Antimicrobial susceptibility testing are bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US)

Research Coverage

This report studies the Antimicrobial susceptibility testing market based on product, design, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the microcatheter market.
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the microcatheter market..
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the microcatheter market.
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（automated）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

抗菌薬感受性試験市場：製品（手動、自動）、タイプ（抗菌、抗真菌）、用途（臨床診断）、方法（ETEST、ディスク拡散、寒天拡散、ジェノタイピング）、エンドユーザー＆地域別 - 2027年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（automated）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?